SLVL

SLVL (VL51) cells, also known as VL51, are a B-cell line derived from a female patient with splenic lymphoma with circulating villous lymphocytes (SLVL). These cells exhibit monoclonality, indicating that they originate from a single cell with abnormal genotypes in the immunoglobulin heavy chain (IgH) gene and the T-cell receptor β (TCR β) gene. The VL51 cell line demonstrates a committed B-cell phenotype, as evidenced by the expression of CD10, CD19, CD20, and surface immunoglobulins. Additionally, VL51 cells are positive for Epstein-Barr virus nuclear antigen (EBNA). Morphologically, SLVL cells resemble lymphocytes and some of them attach to the surface of culture dishes, requiring pipetting during subculture.

Why choose SLVL from AcceGen?

The SLVL cell from AcceGen has various advantages for customers, such as high viability, standardized production, professional operation, and rigorous quality control measures. It was produced in a sterile environment, ensuring its integrity. Extensive testing confirms the absence of  HIV-1, -2, HBV, HCV, bacteria, yeast, and mycoplasma. The cells exhibit high viability, enabling accurate physiological responses. Standardized production protocols ensure consistency, while professional operation and rigorous quality control measures uphold the product’s reliability. These features make the SLVL cell product safe, reliable, and suitable for a variety of research and experimental applications.